- Home
- COCP
as 05-02-2025 4:00pm EST
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first- and-in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI).
| Founded: | 2006 | Country: | United States |
| Employees: | N/A | City: | BOTHELL |
| Market Cap: | 15.3M | IPO Year: | N/A |
| Target Price: | $7.00 | AVG Volume (30 days): | 17.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.72 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.12 - $3.26 | Next Earning Date: | 05-12-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Cocrystal Pharma Inc. News
COCP Breaking Stock News: Dive into COCP Ticker-Specific Updates for Smart Investing
GlobeNewswire
10 days ago
Cocrystal Pharma’s Norovirus Oral Antiviral Candidate Demonstrates Potent Activity Against the Emerging GII.17 Variants
GlobeNewswire
18 days ago
Cocrystal Pharma to Present at Life Science Innovation Northwest 2025 Conference
Zacks Small Cap Research
24 days ago
OTC Markets Hosts Virtual Investor Presentation with Dr. Sam Lee, Co-CEO & President, and Jim Martin, Co-CEO & CFO, of Cocrystal Pharma, with David Bautz, PhD, Senior Analyst at Zacks SCR
Zacks Small Cap Research
a month ago
COCP: Norovirus Challenge Study Planned for 2025…
GlobeNewswire
a month ago
Cocrystal Pharma Reports 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
GlobeNewswire
2 months ago
Life Science Virtual Investor Forum: Presentations Now Available for Online Viewing
GlobeNewswire
2 months ago
Life Sciences Investor Forum Agenda Announced for March 13th
GlobeNewswire
2 months ago
Cocrystal Pharma to Participate in a Fireside Chat at the Zacks SCR Life Sciences Virtual Investor Forum on March 13, 2025
Compare COCP vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "COCP Cocrystal Pharma Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.